Treatment of SARS with human interferons.

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) necessitates effective antiviral treatments.
• Recombinant interferons are being investigated for their antiviral properties against SARS-CoV.

Purpose of the Study:

• To assess the antiviral potential of recombinant interferons against SARS-CoV.
• To compare the efficacy of interferon beta, alpha, and gamma against SARS-CoV in different cell lines.

Main Methods:

• Recombinant interferons (beta, alpha, gamma) were tested against two SARS-CoV clinical isolates (FFM-1 and Hong Kong).
• Viral replication was assessed in Vero and Caco2 cell cultures.
• Selectivity indices were calculated to determine antiviral effectiveness.

Main Results:

• Interferon beta was 5-10 times more effective in Caco2 cells than in Vero cells.
• Interferon alpha inhibited SARS-CoV replication but had a significantly lower selectivity index than interferon beta.
• Interferon gamma showed limited efficacy in Vero cells and was ineffective in Caco2 cells.

Conclusions:

• Interferon beta exhibits promising antiviral activity against SARS-CoV, particularly in Caco2 cells.
• Interferon beta may be a valuable therapeutic agent, potentially used alone or in combination with other drugs for SARS treatment.